HEARTSCIENCES INC C/WTS (TO PUR COM) | 10-K: FY2025 Revenue: USD 4 K

Revenue: As of FY2025, the actual value is USD 4 K.

EPS: As of FY2025, the actual value is USD -9.34.

EBIT: As of FY2025, the actual value is USD -8.353 M.

Revenue for the year ended April 30, 2025 was $4,000, compared to $19,000 for the year ended April 30, 2024, representing a decrease of 79%.

Net Loss: The net loss for the year ended April 30, 2025 was $8.8 million, compared to $6.6 million for the year ended April 30, 2024, representing an increase of 33%.
Gross Margin: Gross margin for the year ended April 30, 2025 was $2,000, compared to $13,000 for the year ended April 30, 2024, representing a decrease of 85%.
Research and Development Expenses: R&D expenses for the year ended April 30, 2025 were $4.4 million, compared to $2.9 million for the year ended April 30, 2024, representing an increase of 52%.
Selling, General and Administrative Expenses: Selling, general, and administrative expenses for the year ended April 30, 2025 were $3.9 million, compared to $3.4 million for the year ended April 30, 2024, representing an increase of 15%.

Operating Cash Flow: Net cash used in operating activities for the year ended April 30, 2025 was $7.4 million, compared to $6.1 million for the year ended April 30, 2024.
Free Cash Flow: Net cash used in investing activities for the year ended April 30, 2025 was $30,000, compared to $125,000 for the year ended April 30, 2024.

Debt Financing: The Company issued an unsecured note in the original principal amount of $2,510,000 to Streeterville Capital, LLC, with net proceeds of approximately $1.9 million after original issue discount and transaction expenses.

The Company plans to continue devoting significant capital resources to R&D, clinical studies, and go-to-market strategies. Additional funding will be required to support the sales launch of its products into the U.S., provide working capital, and support further R&D.

Revenue: As of FY2025, the actual value is USD 4 K.

EPS: As of FY2025, the actual value is USD -9.34.

EBIT: As of FY2025, the actual value is USD -8.353 M.

Revenue for the year ended April 30, 2025 was $4,000, compared to $19,000 for the year ended April 30, 2024, representing a decrease of 79%.

Net Loss: The net loss for the year ended April 30, 2025 was $8.8 million, compared to $6.6 million for the year ended April 30, 2024, representing an increase of 33%.
Gross Margin: Gross margin for the year ended April 30, 2025 was $2,000, compared to $13,000 for the year ended April 30, 2024, representing a decrease of 85%.
Research and Development Expenses: R&D expenses for the year ended April 30, 2025 were $4.4 million, compared to $2.9 million for the year ended April 30, 2024, representing an increase of 52%.
Selling, General and Administrative Expenses: Selling, general, and administrative expenses for the year ended April 30, 2025 were $3.9 million, compared to $3.4 million for the year ended April 30, 2024, representing an increase of 15%.

Operating Cash Flow: Net cash used in operating activities for the year ended April 30, 2025 was $7.4 million, compared to $6.1 million for the year ended April 30, 2024.
Free Cash Flow: Net cash used in investing activities for the year ended April 30, 2025 was $30,000, compared to $125,000 for the year ended April 30, 2024.

Debt Financing: The Company issued an unsecured note in the original principal amount of $2,510,000 to Streeterville Capital, LLC, with net proceeds of approximately $1.9 million after original issue discount and transaction expenses.

The Company plans to continue devoting significant capital resources to R&D, clinical studies, and go-to-market strategies. Additional funding will be required to support the sales launch of its products into the U.S., provide working capital, and support further R&D.